HC Wainwright & Co. Reiterates Buy on Icecure Medical, Maintains $2.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Icecure Medical (NASDAQ:ICCM) and maintained a price target of $2.5.
September 12, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Icecure Medical, maintaining a price target of $2.5. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $2.5 price target by HC Wainwright & Co. indicates a positive outlook on Icecure Medical's stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100